Affibody
Business Services · Sweden · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Scheeles Väg 2, Solna, Stockholm, 171 65...Phone Number
+46 859883800Website
www.affibody.seRevenue
$5.2 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Affibody
Affibody Medical AB is a Swedish biotechnology company focused on developing next generation biopharmaceuticals using its proprietary technology platform. The company aims to create innovative biologics that target specific medical indications, leveraging its scientific expertise for competitive advantage. Affibody's product pipeline includes promising candidates like Izokibep, which is being evaluated for various therapeutic applications. Their intended clients include healthcare providers and patients in need of advanced biopharmaceutical treatments.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Affibody your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Affibody launches new products
Funding: Get notified immidiatlly once Affibody has new funding data
Affibody, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Affibody is spiking on competitors!
Website visits: Recent activity has been detected on your website
Check if Affibody has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Affibody
Earning: See what the market has to say on Affibody recently announced quarterly report
Click to see if Affibody had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at Affibody
Find more new buyers
Company Profile Activity
Activity Insights
Affibody is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Affibody is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Affibody.
Affibody Tech Stack
A closer look at the technologies used by Affibody
Most Recent Scoops
Person-Based
Person-Based
Person-Based
Person-Based
Person-Based
Affibody News & Media
Affibody’s Partner ACELYRIN Announces Top-Line Results from Placebo-Controlled Clinical Trial of Izokibep for Moderate-to-Severe Hidradenitis Suppurativa
• The primary endpoint of HiSCR75 at week 16 did not meet statistical significance in the Non-Responder Imputation (NRI) primary analysis. • HiSCR75 did meet statistical significance at week 16 in a Last Observation Carried Forward sensitivity analysis. • HiSCR response rates of izokibep 160mg weekly (QW) were consistent with Part A open label results, demonstrating early onset of HiSCR100 at week 4, increasing through week 12 to 38% of patients in the Independently ConductedAffibody, ACELYRIN, and Inmagene Biopharmaceuticals Announce Data from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis Presented During 2022 EULAR Congress
• Data suggest efficacy over standard of care for the treatment of psoriatic arthritis • Izokibep was well-tolerated, having a safety profile consistent with previous studies and the IL-17A inhibitor therapeutic class • Supports hypothesis that izokibep offers greater efficacy with high potency and small size, as well as strategy of evaluating IL-17A inhibition’s potential for transformative efficacy across many disease states Solna, Sweden, Los Angeles, USA, and Shanghai, China, June 3, 2022 –ACELYRIN, INC., Affibody AB, and Inmagene Bio Announce Positive Results from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis
Top range efficacy for ACR and PASI scores Proportion of patients with resolution of enthesitis appears differentiating Supports hypothesis that izokibep offers greater efficacy with high potency and small size Supports strategy of evaluating IL-17A inhibition's potential for...Lokon Pharma and Affibody Initiates a Collaboration to Develop Novel Cancer Therapeutics
Uppsala and Solna, Sweden, January 12, 2022. Lokon Pharma AB, a leading biotech company in the area of immunostimulatory gene therapy for cancer delivered by uniquely engineered oncolytic viruses, today announced a collaboration with Affibody AB (“Affibody”) to combine oncolytic viruses with Affibody® molecules. “Lokon’s oncolytic adenovirus platform encodes human immunostimulatory genes to induce anti-tumor immunity in cancer patients. We already have one virus in clinical development, LOAd703,
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Affibody
Sign Up For FreeTo access detailed company insights
Affibody Medical AB is a Swedish biotechnology company focused on developing next generation biopharmaceuticals using its proprietary technology platform. The company aims to create innovative biologics that target specific medical indications, leveraging its scientific expertise for competitive advantage. Affibody's product pipeline includes promi... Read More
